 Tiziana Life Sciences PLC NASDAQ:TLSA said a second patient with Secondary Progressive Multiple Sclerosis SPMS in an ongoing study has shown clinical improvements following three months of treatment with its intranasal drug foralumab. The patient showed improvements based on Positron Emission Tomography PET imaging analysis, a neurologic exam and a timed 25-foot walk test. 